good thank stand welcome laboratory international earn call time participant listen mode speaker presentation question answer session operator instruction would like hand conference host corporate vice president investor relation please ahead corporate vice president investor relation thank good morning welcome laboratory second quarter earn conference call webcast morning foster chairman president chief executive officer executive vice president chief financial officer comment result second quarter follow presentation respond question slide presentation associate today remark post investor relation section website criver webcast replay call available begin roughly hour call today also access investor relation website replay available next quarter conference call like remind safe harbor remark make future expectation plan prospect company constitute forward look statement private security litigation reform actual result differ materially indicate call primarily financial measure believe help investor gain meaningful understand core operate result guidance financial measure mean consider superior substitute result operation prepare accordance accordance regulation find comparable measure reconciliation investor relation section website turn call foster foster chairman president chief executive officer thank good morning strength lead clinical portfolio clearly demonstrate second quarter financial performance robust industry fundamental lead unprecedented client demand across business extremely position succeed environment second quarter organic growth revenue growth teen even normalize last year impact exceed long term double digit target recently provide investor client increasingly choose partner flexible efficient outsource solution scientific depth breadth portfolio unwavering focus flawlessly serve diverse need utilize capability enable drive greater efficiency accelerate speed research clinical development manufacture program believe effort make continue make differentiate competition critical client choose work smaller number offer broader scientific capability sustain demand keenly focus execution strategy strengthen portfolio acquisition gene therapy bioscience late strategically staff capacity accommodate robust demand support client enhance digital enterprise provide greater connectivity exceptional service believe make investment remain position achieve operate margin target believe success strategy reflect second quarter performance provide highlight quarterly revenue surpass million first time million second quarter represent increase last year organic revenue growth increase approximately compare last year impact second quarter greatest impact research model service segment even normalize impact report teen organic growth double digit increase across three business segment operate margin increase basis point year year improvement principally drive segment reflect operate leverage significantly higher sale volume research model part comparison last year impact notwithstanding favorable year year comparison please margin progression first half year track achieve full year operate margin approximately basis point higher last year earn share second quarter increase second quarter last year result widely exceed prior outlook earn growth quarter primarily result exceptional demand environment base second quarter performance expectation sustain demand remainder year increase revenue growth earn share guidance expect organic revenue growth range basis point increase prior range earn share expect range represent year year growth increase midpoint prior outlook attribute exceptional performance outlook success ongoing effort enhance position lead clinical contract research manufacture organization pace scientific innovation fuel significant increase biotech fund approval track near record level first half year like provide detail second quarter segment performance begin segment revenue million second quarter increase organic basis second quarter drive broad base demand discovery safety assessment service small impact segment last year meaningful driver year year growth safety assessment business continue perform exceptionally reflect robust demand biotech global biopharma client price increase book proposal volume continue achieve record high second quarter strength across region major service area strength biotech fund enable client meaningfully invest early stage program unprecedented demand book work next year mention last quarter client expand preclinical pipeline intensify focus complex biologics ensure delay research believe client secure space advance turn provide greater visibility support client continue staff capacity resource necessary effectively manage current demand environment provide client timely efficient high quality service come expect believe investment position safety assessment business support double digit organic revenue growth segment year believe combination robust fund environment deep scientific expertise willingness forge flexible relationship client lead another exceptional quarter discovery business comprehensive portfolio oncology early discovery antibody discovery capability recently enhance distribute acquisition resonate client client increasingly choose outsource integrate discovery partner like despite robust fund biotech client continue maintain limit internal infrastructure instead invest pipeline utilize service move program forward support robust demand biotech global biopharmaceutical client continue strengthen portfolio expand scale science innovative technology combination internal investment strategic partnership strategy enable client remain scientific partner target file beyond solidify position lead nonclinical operate margin increase basis point second quarter leverage robust revenue growth primary driver margin improvement foreign exchange reduce operate margin basis point quarter revenue naturally hedge certain site include safety assessment operation continue expect margin range year revenue million increase organic basis second quarter approximately growth attributable comparison last year relate revenue impact client site closure disruption reduce research model order activity adjust impact growth rate strong research activity across biopharmaceutical academic government client lead business grow target growth rate robust demand research model continue primary driver revenue growth resurgence research activity year model volume exceed level several western market client base transition dominate academic government account vibrant tier biotech client base represent majority client believe expansion client base fuel increase demand accommodate growth continue expand model service offer geographic geographic footprint western southern currently experience strong double digit revenue growth demand research model outside also quite strong believe correlate increase level clinical research conduct biopharmaceutical academic client western market research investment lead biomedical breakthrough drug modality believe global focus scientific innovation sustainable also continue academic client second quarter result relate client shutdown last year recently digital engagement target academic client base research model service also perform benefit strong outsource demand client seek greater flexibility efficiency gain manage proprietary model greater complexity scientific research proprietary model client create reinforce value proposition business client need greater flexibility efficiency also drive demand insourcing solution business particularly initiative provide small large biopharmaceutical client turnkey research capacity site addition expand exist presence client south biohubs also look expand region provide flexible capacity solution client emerge biohubs utilize also provide client collaborative opportunity seamlessly access service enhance speed efficiency research program revenue growth rate self supply business improve second quarter remain target level continue limitation donor access believe cell supply revenue increase second half year donor availability capacity improve expand capability include donor capacity cell supply site state believe enable expand donor base accommodate robust demand broader cell therapy market expect provide critical tool cell gene therapy business believe highly synergistic client enable move client cell therapy program forward cellular product research production operate margin increase second quarter last year significant improvement primarily comparison last year depress margin associate relate client disruption correspond reduction research model order activity revenue manufacture segment million increase organic basis second quarter last year increase drive strong double digit revenue growth biologics test solution microbial solution business meaningful impact segment revenue last year test vaccine vaccine help accelerate biologics revenue growth rate year consistent first quarter microbial solution growth rate second quarter level reflect strong demand endotoxin test system cartridge core reagent geographic region microbial identification service relate client access restriction effectively behind please strength underlie demand endotoxin test platform reform mandate release test client critical quality control test need advantage comprehensive portfolio continue resonate client believe ability provide total microbial test solution enable microbial solution deliver least double digit organic revenue growth year beyond consistent historical trend biologics test business report another exceptional quarter strong revenue growth growth target business robust demand cell gene therapy test service continue primary growth driver rapid increase number cell gene therapy program development approximately program pipeline approximately third preclinical phase expect continue fuel strong growth vaccine work also meaningful driver biologics second quarter growth underlie biologics growth trend remain level even without incremental test revenue believe cell gene therapy continue significant growth driver long term demand vaccine test show sign abate believe commercial production vaccine continue many year come support demand service factor contribute strength demand environment continue build extensive portfolio manufacture service ensure available capacity accommodate client demand manufacture segment second quarter operate margin decline basis point primary driver decline primary driver decline addition business higher production microbial business profitable business solid operate margin margin manufacture segment couple addition third quarter expect full year manufacture margin slightly range however beyond expect headwind gradually dissipate drive efficiency significant growth anticipate generate greater economy scale optimize throughout site early second quarter officially join follow bioscience late please welcome company align business form core cell gene therapy offer believe highly complementary biologics business portfolio whole please initial progress integration addition cell gene therapy service comprehensive portfolio resonate client client begin explore opportunity streamline biologics development workflow service legacy client already look utilize product service within portfolio drive greater efficiency development manufacture activity believe acquisition bioscience viral vector base gene delivery solution fulfill objective create comprehensive cell gene therapy portfolio span major platform gene modify cell therapy viral vector plasmid production combination base operation establish gene modify cell therapy solution believe critical support client seamlessly goal enable client conduct analytical test process development manufacture advance modality scientific partner enable achieve goal drive greater efficiency accelerate speed market result successful execution strategy date believe portfolio strongest ever effort enhance scientific capability deliver flexible outsource solution provide greater value client make important partner client biopharmaceutical industry benefit record fund level experience robust demand essential product service support demand continue enhance value provide client continue move growth strategy forward acquisition strategic partnership remain vital component strategy endeavor expand scientific expertise global reach innovative technology offer client across three business segment invest scientific capability internally necessary staff resource digital enterprise help ensure meet need client successful execution strategy enable enhance position client partner choice concept nonclinical development safe manufacture life save therapeutic also allow achieve longer term financial target double digit organic revenue growth average approximately basis point operate margin improvement beyond conclusion like thank client shareholder support employee exceptional work commitment give additional detail second quarter result update guidance corporate executive vice president chief financial good morning begin remind speak primarily result exclude amortization acquisition relate charge relate primarily global efficiency initiative venture capital strategic investment performance certain advance many comment also refer organic revenue growth exclude impact acquisition foreign currency translation please another strong performance second quarter robust revenue earn share growth outperform prior outlook organic revenue growth include relate last year impact operate margin expansion basis point primary driver behind earn share growth share growth result also reflect favorable comparison second quarter last year experience relate impact client disruption base strong second quarter result expectation underlie strength demand continue increase full year financial guidance expect deliver organic revenue growth range full year primarily result enhance growth prospect year lesser extent favorable rate raise earn share guidance range represent year year growth segment update outlook reflect strong business environment continue expect organic revenue growth high teen drive recovery research model order activity impact pandemic last year exceptional growth outlook unchanged double digit organic revenue growth full year reflect continue strength early stage research activity manufacture segment expect achieve high teen organic revenue growth revise outlook base exceptionally strong demand biologics drive primarily cell gene therapy program increase contribution microbial solution business expect return least double digit growth full year include acquisition recently bioscience manufacture report revenue growth rate expect range regard operate margin expectation segment contribution remain mostly unchanged prior outlook operate margin meaningfully full year range manufacture slightly prior outlook principally reflect addition late lower unallocated corporate contribute second quarter margin expansion total revenue million second quarter compare revenue last year scalable infrastructure enable drive greater efficiency even continue make investment support growth business meet need client continue expect unallocated corporate range percentage revenue full year second quarter rate represent basis point decline second quarter last year decrease favorable excess benefit associate stock base compensation result increase equity exercise award activity higher stock price level quarter benefit partially offset higher expense associate change full year reduce rate outlook range prior outlook rate range principally drive higher benefit stock base compensation total adjust interest expense second quarter million increase million sequentially million year year higher debt balance primarily fund acquisition second quarter outstanding debt balance billion represent gross leverage ratio time subsequent second quarter complete acquisition forma basis include gross leverage ratio remain three time attribute robust free cash flow generation enable repay debt ahead expectation full year expect total adjust interest expense slightly prior outlook range million million primarily reflect accelerate debt repayment free cash flow million second quarter increase million period last year primary driver increase strong second quarter operate performance distribution investment partially offset higher capital expenditure view robust result first half year increase free cash flow outlook million expect free cash flow approximately million full year capex million second quarter last year compare million last year increase primarily time project investment slow defer disruption last year back track continue expect capex approximately million full year summary revise financial guidance full year include recent acquisition find slide third quarter outlook reflect continuation strong demand environment expect growth rate normalize second quarter level relate revenue loss last year accordingly expect organic revenue growth teen range report revenue growth range note forecast meaningful difference first half second half organic growth rate normalize last year impact surprise believe robust demand environment show sign abate expect double digit earn share growth compare last year third quarter level remind operate margin third quarter last year include basis point benefit discovery milestone payment impact year year comparison close please second quarter result include another quarter robust revenue earn free cash flow growth continue focus continue execution strategy achieve financial operational target move forward toward longer term target thank corporate vice president investor conclude comment operator take question